Seroatlas · Human Serome Atlas

TAF6L

TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L

Also known as: PAF65A, TAF6L_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9Y6J9
Gene
TAF6L
Ensembl
ENSG00000162227
Chromosome
11
Canonical length
622 aa
Protein class
Predicted intracellular proteins
Subcellular location
Nucleoplasm

OverviewNCBI Gene

Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes a protein that is a component of the PCAF histone acetylase complex and structurally similar to one of the histone-like TAFs, TAF6. The PCAF histone acetylase complex, which is composed of more than 20 polypeptides some of which are TAFs, is required for myogenic transcription and differentiation. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

622 residues, UniProt reviewed canonical sequence.

>Q9Y6J9|TAF6L
     1  MSEREERRFV EIPRESVRLM AESTGLELSD EVAALLAEDV CYRLREATQN SSQFMKHTKR
    61  RKLTVEDFNR ALRWSSVEAV CGYGSQEALP MRPAREGELY FPEDREVNLV ELALATNIPK
   121  GCAETAVRVH VSYLDGKGNL APQGSVPSAV SSLTDDLLKY YHQVTRAVLG DDPQLMKVAL
   181  QDLQTNSKIG ALLPYFVYVV SGVKSVSHDL EQLHRLLQVA RSLFRNPHLC LGPYVRCLVG
   241  SVLYCVLEPL AASINPLNDH WTLRDGAALL LSHIFWTHGD LVSGLYQHIL LSLQKILADP
   301  VRPLCCHYGA VVGLHALGWK AVERVLYPHL STYWTNLQAV LDDYSVSNAQ VKADGHKVYG
   361  AILVAVERLL KMKAQAAEPN RGGPGGRGCR RLDDLPWDSL LFQESSSGGG AEPSFGSGLP
   421  LPPGGAGPED PSLSVTLADI YRELYAFFGD SLATRFGTGQ PAPTAPRPPG DKKEPAAAPD
   481  SVRKMPQLTA SAIVSPHGDE SPRGSGGGGP ASASGPAASE SRPLPRVHRA RGAPRQQGPG
   541  TGTRDVFQKS RFAPRGAPHF RFIIAGRQAG RRCRGRLFQT AFPAPYGPSP ASRYVQKLPM
   601  IGRTSRPARR WALSDYSLYL PL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TAF6L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.49
Highest tissue expression
22 nTPM

Expression across tissuesHPA

Tissue

  • liver: 22 nTPM
  • skeletal muscle: 18 nTPM
  • pituitary gland: 15 nTPM
  • pancreas: 13 nTPM
  • endometrium: 13 nTPM
  • thyroid gland: 13 nTPM

Single-cell type

  • syncytiotrophoblasts: 31 nCPM
  • breast myoepithelial cells: 31 nCPM
  • retinal ganglion cells: 31 nCPM
  • cardiomyocytes: 29 nCPM
  • myonuclei: 26 nCPM
  • cytotrophoblasts: 25 nCPM

Immune cell

  • NK-cell: 1.1 nTPM
  • eosinophil: 0.9 nTPM
  • myeloid DC: 0.9 nTPM
  • naive CD4 T-cell: 0.9 nTPM
  • plasmacytoid DC: 0.9 nTPM
  • intermediate monocyte: 0.8 nTPM

Brain region

  • cerebral cortex: 23 nTPM
  • medulla oblongata: 23 nTPM
  • pons: 22 nTPM
  • midbrain: 21 nTPM
  • basal ganglia: 21 nTPM
  • cerebellum: 20 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.52
gnomAD pLI
0.07
gnomAD missense Z
0.85
DepMap mean gene effect
-0.35
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TAF6L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TAF6L as an antibody target. Whether an autoantibody or antibody against TAF6L could matter depends on whether native TAF6L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TAF6L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TAF6L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TAF6L. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...